ARTICLE / CLIENT ALERT
Stark and AKS Final Rules Will Facilitate Donations of EHR and Cybersecurity Technology and Services
December 22, 2020
Read time: 14 min
On November 20, 2020, the Centers for Medicare and Medicaid Services and Office of Inspector General released final rules amending the regulations to the Stark Law and the Anti-Kickback Statute and Beneficiary Inducement Civil Monetary Penalty Law. As part of these final rules, the agencies liberalized the requirements under the existing exception and safe harbor for donations of electronic health record items and services, and created a new exception and safe harbor to allow donations of cybersecurity technology and related services.
On November 20, 2020, the US Department of Health & Human Services (HHS) released final rules amending the regulations to the physician self-referral law (Stark Law) (Stark Rule) and the Anti-Kickback Statute (AKS) and Beneficiary Inducement Civil Monetary Penalty Law (collectively, AKS Rule) in connection with HHS’s Regulatory Sprint to Coordinated Care. As part of the Stark Rule and the AKS Rule, the Centers for Medicare and Medicaid Services (CMS) and HHS Office of Inspector General (OIG) liberalized the requirements under the existing exception and safe harbor for donations of electronic health record (EHR) items and services (EHR Exception and Safe Harbor), and created a new exception and safe harbor for donations of cybersecurity technology and related services (Cybersecurity Exception and Safe Harbor). This On the Subject analyzes the changes to the EHR Exception and Safe Harbor and the new Cybersecurity Exception and Safe Harbor. For additional analysis and insights on the final rules, visit McDermott’s Regulatory Sprint Resource Center.
Modifications to the EHR Exception and Safe Harbor
CMS and OIG originally issued the EHR Exception and Safe Harbor in 2006, protecting certain donations (e.g., licenses and other arrangements for less than the fair market value) of interoperable EHR software or information technology and training services to physicians and other referral sources. By meeting the conditions of the EHR Exception and Safe Harbor, a donor and donation recipient will not violate the Stark Law’s self-referral prohibition or AKS’s prohibition on remuneration to induce referrals of items and services covered by federal health care programs.
Scope of Protected Donors
The current EHR Exception protects donations from entities that provide hospital services and other designated health services, other than laboratory companies, while the current EHR Safe Harbor protects donations from individuals or entities, other than laboratory companies, that provide services covered by a federal health care program and submit claims or requests for payment, either directly or through reassignment, to the federal health care program as well as health plans.
CMS did not change the scope of protected donors for the EHR Exception. OIG, on the other hand, expanded the scope of protected donors to include entities, such as accountable care organizations and health systems, that are comprised of individuals or entities that provide services covered by federal health care programs.
Cybersecurity Software and Services
In the preamble to the Stark Rule and the AKS Rule, HHS clarified that the EHR Exception and Safe Harbor have always protected donations of certain cybersecurity software and services, such as cybersecurity features of the EHR. The agencies amended the EHR Exception and Safe Harbor to explicitly include cybersecurity software and services that protect an EHR as permissible donations, as long as the predominant purpose of the software or service is cybersecurity associated with EHR functions.
Replacement EHR Technology
The agencies removed the current EHR Exception and Safe Harbor condition that the donor not know that the donation recipient possesses EHR items and services equivalent to those included in the donation. This change will allow donors to donate a replacement EHR to referral sources that already have another certified EHR, and addresses comments from physician practices and others that the current condition unnecessarily locks them into an EHR that does not meet their needs.
Recipient Cost Sharing Condition
Currently the EHR Exception and Safe Harbor require the donation recipient to pay at least 15% of the donor’s cost of donated EHR items and services in advance of receipt of all items and services. In the final rules, CMS and OIG retained the 15% cost contribution requirement for the initial donation (or a donation of replacement items and services) in advance of receipt of the items and services. For items or services donated after the initial donation (or the replacement donation), CMS amended the EHR Exception to require the donation recipient to pay its cost contribution amount “at reasonable intervals,” while OIG amended the EHR Safe Harbor to remove the prepayment requirement for “updates.” It is not clear from the text of the EHR Safe Harbor and the AKS Rule preamble guidance whether OIG uses the term “updates” to limit the types of donations following the initial donation that can be paid in arrears by the donation recipient to upgrades to existing functionality, bug fixes and similar software maintenance services. In addition, based on the Stark Rule preamble, it is unclear whether CMS intends to except services other than updates from the prepayment condition despite its omission of the term “updates” from the EHR Exception itself.
For example, if a hospital donates the right to access and use a shared EHR instance and EHR implementation services, and subsequently provides ongoing hosting, maintenance and support services on a periodic (e.g., quarterly) basis to a referring physician practice, the plain language of the Stark Exception appears to permit the donor to collect payments in arrears for the periodic services after the initial period of service, rather than collecting payment before the beginning of the service period. However, as noted above, it is unclear whether the agencies would consider such ongoing services to be exempt from the prepayment requirement under the EHR Exception based on the Stark Rule preamble discussion of “updates” following the initial donation or under the EHR Safe Harbor based on its use of the term “updates.”
Interoperability Requirement
To be protected under the current EHR Exception and Safe Harbor, donated EHR items and services must be “interoperable.” Donated EHR software is deemed to be interoperable if it has been certified by a certifying body authorized by the HHS Office of the National Coordinator for Health Information Technology (ONC) to a then-applicable edition of the EHR certification criteria under ONC’s Health IT Certification Program.
HHS retained this deeming construct but clarified that the software must have a current certification on the date it is donated. HHS also made editorial changes to align the EHR Exception and Safe Harbor with ONC’s changes to its Health IT Certification Program regulations.
Information Blocking Prohibition
CMS and OIG both removed the third condition of the current EHR Exception and Safe Harbor that prohibits donors (and anyone acting on their behalf) from taking actions to limit or restrict the interoperability of the donated items or services. The condition was designed to prevent data and referral lock-in and to encourage data exchange. In 2016, Congress adopted the 21st Century Cures Act, which prohibits information blocking and authorizes HHS to issue exceptions to the prohibition. ONC issued a final rule in March 2020 to implement the prohibition and establish exceptions to the information blocking prohibition (ONC Final Rule). By removing the condition addressing information blocking, HHS indicated that it will rely on the ONC Final Rule instead of the EHR Exception and Safe Harbor to prevent information blocking. For more information on the ONC Final Rule, see our Special Report.
Sunset Provisions
The specter of a sunset date has loomed over the EHR Exception and Safe Harbor since their creation in 2006. CMS and OIG kicked the can down the road in 2013 but now have removed the sunset provision altogether. The original sunset provision was based on the expectation that the need to protect EHR donations would decrease as EHR use became the standard of practice. The agencies no longer believe that the need to protect EHR donations will disappear as the industry achieves widespread adoption—which the agencies acknowledged has largely happened. HHS explained its change of heart by pointing to new entrants into medical practice, aging EHRs at existing practices, and emerging and improved technologies.
The Takeaway
Health systems and other donors of EHR items and services should review their template EHR donation agreements and determine whether to make changes to take advantage of the more favorable conditions of the amended EHR Exception and Safe Harbor. While donors may choose to delete provisions specifically addressing the sunset date, they should consider adding or retaining a more general provision addressing changes in law. Donors should also consider updates to the template donation agreement to address information blocking concerns under the ONC Final Rule. For more information about the information blocking provisions of the ONC Final Rule and their implications for EHR donation agreements, see our On the Subject.
Creation of Cybersecurity Exception and Safe Harbor
In addition to clarifying that the EHR Exception and Safe Harbor permit certain cybersecurity donations, CMS and OIG created the Cybersecurity Exception and Safe Harbor to protect the donation of certain cybersecurity technology and related services. The Cybersecurity Exception and Safe Harbor are intended to help improve the health care industry’s overall cybersecurity posture by permitting donations to address the growing cyber threats that the industry faces.
CMS and OIG appear to have used the EHR Exception and Safe Harbor conditions as a starting point for the Cybersecurity Exception and Safe Harbor and then removed certain conditions.
Covered Technology and Services
The Cybersecurity Exception and Safe Harbor permit the donation of cybersecurity technology and related services. CMS and OIG defined “cybersecurity” to mean “the process of protecting information by preventing, detecting, and responding to cyberattacks” based on the definition included in the Framework for Improving Critical Infrastructure Cybersecurity of the National Institute for Standards and Technology. The agencies defined the term broadly to avoid unintentional limitations on what may be donated and obsolescence with the passage of time.
The agencies also broadly defined “technology” to mean “any software or other types of information technology.” The definition is intended to be agnostic to the type of cybersecurity technology and broad enough to cover technology that is neither software nor a service as those terms are generally conceived, such as application programing interfaces. Unlike the EHR Exception and Safe Harbor, the Cybersecurity Exception and Safe Harbor do not exclude certain hardware from the definition of technology that may be donated. However, the agencies will only permit hardware donations if the hardware is not integrated with multifunctional equipment and, as discussed below, is used predominantly to implement, maintain or reestablish effective cybersecurity.
Necessary and Used Predominantly for Effective Cybersecurity
The donated technology and related services must be necessary and used predominantly to implement, maintain or reestablish effective cybersecurity. Accordingly, the core function of the donation must be to protect information by preventing, detecting and responding to cyberattacks. The table below identifies examples of technology and services that could meet this condition, according to the agencies:
| Potentially Protected Technology | Potentially Protected Services |
| Software that provides malware prevention | Any services associated with developing, installing and updating cybersecurity software |
| Software security measures to protect endpoints that allow for network access control” | Any kind of cybersecurity training services |
| Business continuity software that mitigates the effect of cyberattacks | Any kind of cybersecurity services for business continuity and data recovery services to ensure that the recipient’s operations can continue during and after a cyberattack |
| Data protection and encryption | Any services associated with performing a cybersecurity risk assessment or analysis, vulnerability analysis or penetration test |
| Email traffic filtering | Any services associated with performing a cybersecurity risk assessment or analysis, vulnerability analysis or penetration test |
The agencies also offered the following examples of donations not protected by the Cybersecurity Exception and Safe Harbor: installation or improvement of physical safeguards (such as upgraded wiring or high security doors), and donations of technology and services with multiple general uses outside of cybersecurity, such as general help desk services.
Does Not Directly Take into Account Volume or Value of Referrals
The first condition of the Cybersecurity Exception and Safe Harbor prohibits the donor from directly taking into account the volume or value of referrals or other business generated between the parties when determining both the eligibility of a potential recipient for the donation or the amount or nature of the donation. The first condition of the Cybersecurity Safe Harbor also expressly prohibits the donor from conditioning the donation or the amount or nature of the donation on future referrals.
Notwithstanding this condition, the agencies acknowledged that donors will provide cybersecurity technology and services to individuals and entities that connect to their systems, which would include those that refer to the donor or receive referrals from the donor. The agencies noted that this condition does not require a donor to make donations to every individual or entity that connects to its systems, and permits certain selective criteria as long as the criteria do not directly take into account referrals or other business generation.
Unlike the corresponding condition in the EHR Exception and Safe Harbor, the Cybersecurity Exception and Safe Harbor do not include a deeming provision that identifies certain selection criteria that would automatically be determined to meet the condition. The agencies stated that they do not believe that cybersecurity donations present the same types of risks as EHR donations (because cybersecurity donations are further removed from referrals than EHR donations) and that therefore a list of selection criteria is unnecessary.
Donation Not a Condition of Doing Business with Donor
The second condition of the Cybersecurity Exception precludes the donation recipient (including the referring physician, the physician’s practice, or the practice’s employees and other staff) from making a cybersecurity donation, or the amount or nature of the donated technology or services, a condition of doing business with the donor. Similarly, the Cybersecurity Safe Harbor does not permit the donation recipient or the recipient’s practice (or any affiliated individual or entity) to make the donation, or its amount or nature, a condition of doing business with the donor.
No Cost Sharing Condition
Unlike the EHR Exception and Safe Harbor, the Cybersecurity Exception and Safe Harbor do not require that the recipient pay any of the costs (e.g., 15%) of the donation and do not limit the scope of potentially protected recipients. OIG noted that donations may be made to patients under the EHR Safe Harbor. Donors are free to require recipients to contribute to the cost, however, as long as the determination of a contribution amount does not take into account the volume or value of referrals or other business generation between the parties.
Written Agreement
Both agencies require the donation arrangement to be documented in writing. OIG additionally requires that the writing be signed, and specifies that the writing must include a general description of the donated technology and services.
When crafting donation agreements, donors should review their license agreements for cybersecurity software to ensure that they have rights to extend the software to third parties.
Donors should also carefully consider the addition of limitations of liability and other commercial terms to a donation agreement to protect the donor from claims that the donated technology and services failed to fully protect the donation recipient or third parties from a cyberattack.
Additional Safe Harbor Condition
The Cybersecurity Safe Harbor also precludes the donor from shifting the cost of the donated cybersecurity technology or services to any federal health care program. Accordingly, the donation should not be included in a reimbursable cost center on a Medicare or Medicaid cost report.
The Takeaway
The new Cybersecurity Exception and Safe Harbor are broader and include fewer conditions than the EHR Exception and Safe Harbor for purposes of cybersecurity technology and related service donations, and provide a useful pathway for hospitals and other donors to protect their systems through donations to connected recipients.
Please do not hesitate to contact your regular McDermott lawyer or any of the authors of this On the Subject if you have questions or need assistance with your EHR or cybersecurity donation arrangements. For more information on the various elements of these final rules, please refer to our Regulatory Sprint Resource Center.

COVID-19 Vaccine FAQs for Employers
ARTICLE
COVID-19 Vaccine FAQs for Employers
December 22, 2020
Read time: 2 min
On December 16, 2020, the Equal Employment Opportunity Commission (EEOC) issued its first direct guidance for employers regarding COVID-19 vaccines approved or authorized by the Food and Drug Administration (FDA). The EEOC is responsible for enforcing federal laws against job discrimination and harassment.

What the “Essential Medicines” Executive Order Means for Federal Contractors and the FDA
ARTICLE
What the “Essential Medicines” Executive Order Means for Federal Contractors and the FDA
December 21, 2020
Read time: 2 min
President Donald Trump has issued the Executive Order on Ensuring Essential Medicines, Medical Countermeasures and Critical Inputs Are Made in the United States (the Order). The Order is aimed at ensuring that there is an adequate supply in the United States of Essential Medicines, Medical Countermeasures and Critical Inputs (i.e., the ingredients and components used to make essential medicines and medical countermeasures) (collectively, “Products”) in the face of chemical, biological, radiological and nuclear threats and public health emergencies, such as infectious disease outbreaks.
To achieve these goals, the Order sets forth requirements for executive departments and agencies involved in the procurement of Products.
SPACs Should Consider Targeting Bankruptcy Sales
ARTICLE
SPACs Should Consider Targeting Bankruptcy Sales
December 21, 2020
Read time: 1 min

Legislative Decision of 17 December 2020 on Adjustment of Pandemic-Related Regulations for Commercial Lease Agreements
ARTICLE / CLIENT ALERT
Legislative Decision of 17 December 2020 on Adjustment of Pandemic-Related Regulations for Commercial Lease Agreements
December 21, 2020
Read time: 2 min
Following the decision of the Federal Chancellor and the heads of government of the federal states, the German Federal Parliament passed a law on December 17 2020 to adapt pandemic-related regulations, inter alia, for commercial lease agreements.

Precautionary Measures to protect the Family Assets
ARTICLE
Precautionary Measures to protect the Family Assets
December 18. 2020
Read time: 2 min
Dr. Nils Christian Wighardt and Jonathan Storz explain various measures that ensure the ability of entrepreneurial families to act even in unforeseeable crisis situations. The sudden disappearance of Tengelmann heir Karl-Erivan Haub or the Corona pandemic show how quickly such measures can become relevant.
Launching Advanced Talent Acquisition Tools to Tackle Global Employer Recruiting Challenges in The Wake of COVID-19
ARTICLE
Launching Advanced Talent Acquisition Tools to Tackle Global Employer Recruiting Challenges in The Wake of COVID-19
December 20, 2020
Read time: 1 min

Mexico’s Reportable Transactions Rules in Effect January 1
ARTICLE / CLIENT ALERT
Mexico’s Reportable Transactions Rules in Effect January 1
December 17, 2020
Read time: 8 min
Beginning January 1, 2021, Mexico’s reportable transaction rules require either a taxpayer or a tax advisor to report to the Mexican tax authorities any transactions that are designed, marketed, organized, implemented or administered to provide a tax benefit to the taxpayer.
What is a Reportable Transaction?
A reportable transaction is considered to be any transaction that generates or may generate, directly or indirectly, a tax benefit in Mexico and has any of the following characteristics:
- Prevents foreign authorities from exchanging tax or financial information with Mexican tax authorities.
- Avoids the application of the preferential tax regime (“REFIPRE”) or of transparent tax entities and foreign instruments.
- Shifts tax losses to people other than those who generated them.
- Consists of a series of interconnected payments or operations that return all or part of the amount of the first payment that is part of said series, to the person who made it or one of its partners, shareholders or related parties.
- Is a hybrid structure that applies a tax treaty signed with Mexico.
- Involves operations between related parties in which:
- Intangible assets difficult to value are transferred in accordance with The Organisation for Economic Co-operation and Development’s (OECD) Transfer Pricing Guidelines for Multinational Companies and Tax Administrations;
- Business restructurings with no consideration paid have the effect of reducing operating profit by more than 20%;
- The use of goods and rights are transferred or granted without consideration;
- No reliable comparables exist, as they are operations that involve unique or valuable functions or assets; or
- A unilateral protection regime granted in terms of foreign legislation is used in accordance with OECD’s Guidelines on Transfer Pricing for Multinational Companies and Tax Administrations.
- Avoids establishing a permanent establishment in Mexico under Mexican income tax law and the treaties to avoid double taxation signed by Mexico.
- Involves the transfer of a fully or partially depreciated asset, which allows its depreciation by another related party.
- Involves a hybrid mechanism defined in accordance with a particular section of Mexican income tax laws.
- Avoids the identification of the beneficial owner of income or assets, including through the use of foreign entities or legal figures whose beneficiaries are not designated or identified at the time of its incorporation or at any time.
- Are operations carried out to obtain tax benefits contemporaneous with the imminent expiration of tax losses.
- Avoids applying the additional rate of 10% in certain cases provided in Mexican income tax law.
- Exists certain related-party leases.
- Exists certain operations in which there is a greater than 20% discrepancy between tax and accounting records.
Who is required to report?
Taxpayers and tax advisors have the obligation to report reportable transactions.
A tax advisor is any individual or entity that, in the ordinary course of its activity, carries out tax advisory services and is responsible for or is involved in the design, marketing, organization, implementation or administration of the entirety of a reportable transaction or who makes the entire reportable transaction available for implementation by a third party.
The tax advisers required to make disclosures are those who are considered residents in Mexico or residents abroad who have a permanent establishment in Mexico in accordance with Mexican income tax laws, provided that the activities attributable to said permanent establishment are those carried out by a tax advisor.
When a tax advisor residing abroad has a permanent establishment or a related party in Mexico, there is a rebuttable presumption that the tax advice was provided by the latter. This presumption will also be applicable when a third party who is a resident in Mexico or a permanent establishment of a resident abroad carries out tax advisory activities under the same trademark or trade name as the tax advisor residing abroad.
A reportable transaction must be disclosed regardless of the taxpayer’s tax residence, provided that the taxpayer obtains a tax benefit in Mexico.
If several tax advisors are obliged to disclose the same reportable transaction, they will be considered to have complied with the disclosure requirement if one of them discloses said transaction on their behalf. Additionally, such an advisor must issue a certificate to the other tax advisors who are released from the reporting obligation indicating that the transaction has been disclosed.
Alternatively, taxpayers are required to make the disclosure of reportable transactions when the tax advisor does not provide the taxpayer with the identification number of the reportable transaction issued by the tax authorities or does not provide a certificate stating that the transaction is not reportable.
A taxpayer must also disclose reportable transactions that the taxpayer designs, organizes, implements or administers. In certain cases, the tax advisers who are individuals may be exempt from the disclosure requirement provided that certain provisions of the Mexican tax code are met.
If a reportable transaction is designed, commercialized, organized, implemented or administered by a person who does not meet the definition of a tax adviser under Mexican laws or is a non-Mexican resident and has no permanent establishment in Mexico, then the taxpayer must disclose the reportable transaction.
Two other scenarios in which a taxpayer rather than the tax advisor is required to disclose the reportable transaction are when there is a legal impediment for the tax advisor to reveal the reportable transaction and when the taxpayer has entered into an agreement with the tax advisor to make the disclosure.
It is important to note that taxpayers obligated to disclose reportable transactions are tax residents of Mexico and non-Mexican tax residents that have a permanent establishment in Mexico, and they carry out transactions with non-Mexican, related parties that generate tax benefits in Mexico for the non-Mexican tax residents.
What information must be disclosed to the Mexican Tax Authorities?
Either the taxpayer or the tax advisor must disclose the name, address and tax identification number for the tax advisor or the taxpayer, as well as information related to other involved advisors, if applicable. In addition, the reporting must include (i) a detailed description of each of the steps of the transaction along with a technical explanation of the Mexican and foreign tax rules; (ii) a description of the tax benefit obtained or expected; and (iii) the tax years for which the transaction was or will be implemented. The tax authorities may request additional information after the initial filing is made. In which case, the tax advisor or taxpayer will have 30 days to respond to the information request, which must be made under penalties of perjury. The disclosure of a reportable transaction does not imply that the Mexican tax authorities have accepted or rejected the tax effects of the transaction.
Pursuant to the regulations issued on November 18, 2020, either the taxpayer or the tax advisor must report the following information: (i) a diagram detailing all the transactions (legal acts or facts) that are part of the plan, project, proposal, advice, instruction and/or recommendation that makes up the reportable transaction; (ii) the country or jurisdiction where the entities involved within the reportable scheme are or will be located, as well as the jurisdiction where the transactions (legal acts or facts) which make up the reportable scheme will take place; and (iii) the background and conclusions of the context of the reportable transaction, as well as the legal arguments and the premises upon which the legal interpretation is based.
In addition, in the case of a customized transaction, the regulations require that tax advisors or taxpayers provide the Mexican tax authority the following information: (i) the exact date or approximate date on which the transactions (legal acts or facts), which integrate the reportable scheme, will take place; (ii) the estimated value or amount of such transactions (if the beneficiary taxpayers are assisted or will be assisted by individuals, entities or legal entities abroad or in Mexico, as well as their identification data including their tax residency or location; and (iii) indicate if the participants in the reportable scheme are considered as related parties in terms of the Mexican law.
When to report
Generalized reportable transactions must be disclosed no later than 30 days after the first contact is made for their commercialization. First contact is deemed to be made for commercialization when the necessary measures are taken so that third parties know the existence of the reportable transaction.
Custom-tailored reportable transactions must be disclosed no later than 30 days after the day the transaction is available to the taxpayer for implementation, or the first legal event or act that forms part of the transaction is performed, whichever comes first. Tax advisers and taxpayers obliged to disclose reportable transactions may do so from the moment they have finalized their design.
Penalties
The rules provide a set of parameters designed to penalize tax advisors and the taxpayers that have infringed on their respective obligation to disclose a reportable transaction. Penalties imposed on tax advisors for such infringement can be as high as approximately USD 1 million (exchange rate being approximately 20 Mexican pesos per US dollar). Penalties imposed on taxpayers who infringe on their obligation are fined up to the value of the tax benefit received from the reportable transaction.
If a taxpayer does not disclose a reportable transaction or makes an incomplete disclosure or one with errors, the tax authorities may impose a penalty equivalent to an amount between 50% and 75% of the tax benefit obtained or expected to obtain.

Regulated Funds: SEC Adopts New Fair Valuation Framework
ARTICLE / CLIENT ALERT
Regulated Funds: SEC Adopts New Fair Valuation Framework
December 17, 2020
Read time: 22 min
On Dec. 3, 2020, the SEC adopted a new rule under the Investment Company Act of 1940, as amended, (“1940 Act”) addressing the valuation practices of registered investment companies and business development companies (“funds”).[1] Rule 2a-5 (“Rule”) represents an effort to modernize and codify a principles-based framework for fair value determination of fund investments. Most significantly, in a departure from prior SEC guidance and interpretation, and subject to several requirements and the continued oversight of the board, the Rule allows a fund’s board to designate the fair value determination of the fund’s investments to the fund’s investment adviser, or, in the case of an internally managed fund, to an officer of the fund (each, a “valuation designee”), rather than requiring the board to make the final determination itself.[2]
The Rule, which was first proposed in April 2020,[3] provides considerable benefit to funds that invest from time to time in illiquid securities that do not have readily available market quotations, particularly when such illiquid investments represent a relatively small percentage of a fund’s overall portfolio.[4] With the assistance of investment advisers, boards of such funds are currently required to engage in a time-consuming and intensive process to make fair value determinations for these hard to value investments on a regular basis. Under the Rule, these boards will retain oversight of the valuation process, but can formally designate the fair value determination with respect to such illiquid assets, including the specific process for making fair value determinations, to a valuation designee.
Notably, a number of the requirements imposed under the Rule, including segregating the valuation process from the portfolio management function, may make reliance by funds that primarily invest in illiquid assets, such as business development companies (“BDCs”), less attractive. In particular, BDCs and other similar illiquid-focused funds tend to have well-developed procedures for boards to interact with both advisory personnel and third-party valuation firms, where appropriate, as part of the periodic valuation process. As a result, the boards of such funds may be less willing to delegate their responsibilities and therefore potentially reduce their visibility with respect to, and integral participation in, the valuation process. In addition, advisers to such funds may be less willing to segregate portfolio management personnel from the valuation process, as would be required under the Rule.
In contrast, open-end funds, including mutual funds and exchange-traded funds, may be more likely to take advantage of the flexibility afforded under the Rule. Specifically, such open-end funds would normally only have a small percentage of their respective portfolios invested in illiquid investments, if any. The ability to adopt detailed procedures to permit an open-end fund’s board to delegate the valuation of such illiquid investments to the fund’s adviser would, therefore, allow such funds to more easily and efficiently handle assets that unexpectedly become illiquid, while also treating such investments in a manner that would be more consistent with how liquid investments are presently valued by most open-end funds. In addition, the delegation of fair value determinations provided under the Rule would ease the burden of setting an open-end fund’s net asset value, and therefore the value of its investment portfolio, on a daily basis.
Although the Rule addresses funds regulated under the 1940 Act, the Rule and the release adopting the Rule (“Adopting Release”) may also provide insight into certain valuation-related matters with respect to investment advisers that advise private funds, including relating to potential conflicts of interest in the valuation process. In addition, advisers that primarily advise private funds but also advise or sub-advise regulated funds should familiarize themselves with the provisions of the Rule and may need to update their valuation procedures to reflect certain requirements of the Rule.
Background
The proper valuation of a fund’s investments plays a crucial role in various aspects of a fund’s operations, including the determination of a fund’s net asset value, which for many funds determines the price at which a fund’s shares are offered and redeemed. Valuation of investments also affects the accuracy of a fund’s asset-based and performance-based fee calculations and impacts a fund’s ability to comply with its investment policies and restrictions. However, the SEC has not formally addressed fund valuation practices since the early 1970s, when it issued Accounting Series Releases Nos. 113 and 118 (“ASRs”) which still provide the basis for determination of fair value of securities today, along with guidance from the Financial Accounting Standards Board, particularly ASC Topic 820. The staff of the SEC also has provided guidance on valuation issues through a series of no-action letters.
Section 2(a)(41) of the 1940 Act defines “value” with respect to assets held by registered investment companies.[5] The definition differentiates between assets for which market quotations are “readily available” and those for which market quotations are not readily available. When market quotations are not readily available, value is defined as fair value as determined in good faith by the fund’s board of directors.
The SEC notes in the Adopting Release that since the last comprehensive review of valuation fifty years ago, there have been significant developments in market and investment practices impacting funds and the valuation of their investments, as well as several regulatory changes. Funds now invest in more complex securities that present new valuation challenges. As an example, BDCs, which did not exist when the ASRs were issued, typically invest in the securities of small and middle-market companies that must be fair valued on at least a quarterly basis. Communications and technology advances have also resulted in greater availability of pricing information, as well as greater availability of other data that may be relevant in the valuation process.
The enactment of the Sarbanes-Oxley Act of 2002, which established the Public Company Accounting Oversight Board, the adoption of Rule 38a-1 under the 1940 Act requiring funds to adopt compliance policies and procedures (including with respect to fair value) and the issuance of ASC Topic 820 by the Financial Accounting Standards Board all have significantly impacted the fund valuation process. These regulatory developments, coupled with more complex and harder to value securities held by funds, have resulted in boards relying more heavily on the expertise of investment advisers and third-party pricing services in an effort to effectively fulfill the fair value determination obligations set forth in Section 2(a)(41). While boards currently are responsible for determining the methodologies used to fair value fund investments, they typically rely on the adviser and pricing services for the day-to-day calculation of fair values.
Acknowledging the reality of current board practices and the developments discussed above, the Rule provides that the board may designate the fair valuation determination for investments to a valuation designee, subject to oversight of the board and certain reporting and recordkeeping requirements.[6] It also provides a standardized framework for the actions and functions that are required in order to determine fair value in good faith. In addition, the Rule provides a definition of “readily available market quotation,” which is not otherwise defined in the 1940 Act or the rules thereunder.
Performance of Fair Value Determinations
As noted above, the board of a fund is responsible for determining in good faith the fair value for fund investments for which market quotations are not readily available.[7] The Adopting Release acknowledges that boards typically are not involved in the day-to-day valuation tasks that would be required to determine fair value and instead in practice often allocate this function to the fund’s adviser, subject to the board’s supervision. In acknowledging this practical reality, the Rule allows the board to designate the actual fair value determination to a valuation designee which would carry out the functions described in the above section, subject to the board’s oversight.
Oversight. The Adopting Release makes it clear that, even where a board has designated fair value determination to a valuation designee, the board retains responsibility for active oversight of such valuation designee. The Adopting Release notes that boards should approach this oversight with a “skeptical and objective view,” particularly with respect to valuation risks and potential conflicts of interest. The Adopting Release encourages board members to seek out and review relevant information as may be necessary to be fully informed about the fund’s fair value process. It also notes that the SEC expects that boards will utilize an appropriate “level of scrutiny” based on the fund’s valuation risk, and that this scrutiny should be proportionate to the level of subjectivity involved in determining fair value for an investment. The Adopting Release notes the expectation that boards will periodically review the financial resources, technology, staff and expertise of the valuation designee, as well as the reasonableness of the valuation designee’s reliance on other fund service providers, with an aim to evaluate the appropriateness of the fair value process.
The Adopting Release also focuses on concerns relating to potential conflicts of interest that may arise as a result of the adviser or other service providers having incentives to improperly value fund assets. It notes that a fund’s adviser may benefit from improper valuations, which could increase fees or improve returns. In particular, the Adopting Release admonishes boards to seek to identify potential conflicts of interest, monitor such conflicts and take reasonable steps to manage such conflicts.
Board Reporting. Pursuant to the Rule, a valuation designee that the board has designated to perform fair value determinations must provide to the board certain periodic reports and prompt notification and reporting on matters materially affecting the fair value of investments. On a quarterly basis, the valuation designee must provide a summary or description of material fair value matters occurring during the prior quarter, as well as any other information requested by the board.[8] The valuation designee must also provide the board a written assessment of the adequacy and effectiveness of the valuation designee’s fair valuation process, on at least an annual basis.[9] The valuation designee must also provide prompt reporting to the board (within five business days) on matters that could materially affect the fair value of investments.[10] As noted in the Adopting Release, a board must also inquire about any material matters of which the board becomes aware, and take reasonable steps to ensure they are addressed.
Specify Responsibilities. If fair value determination is designated to a valuation designee, the valuation designee must specify the titles and functions of the persons responsible for determining the fair value of the investment, and must reasonably segregate the process of making fair value determinations from the portfolio management of the fund, in order to avoid potential conflicts of interest. Although the Adopting Release notes that portfolio managers may have relevant insight into the process for determining fair value for investments, the inherent conflicts of interest that are present because portfolio management personnel are usually compensated based on the returns of the fund make it inappropriate for a portfolio manager to make the fair value determination. The Rule specifies that a portfolio manager may not determine, or effectively determine by exerting substantial influence on, the fair values of portfolio investments.
Fair Value Determination Under The Rule
In order to determine fair value in good faith of a fund’s investment, as required by Section 2(a)(41), the Rule lays out the following actions and functions that are required to be undertaken either by the board, or if the board has designated fair value determination to a valuation designee, by the valuation designee:
Assess and Manage Valuation Risks. The Rule requires the periodic assessment of material risks associated with valuation. The Adopting Release includes a non-exhaustive list of examples of the types and sources of such risks, including the types of investments held or intended to be held by a fund, potential market or sector dislocations, the extent to which unobservable inputs are utilized in the valuation methodology and reliance on service providers and limitations of their experience. The Rule does not prescribe the specific valuation risks to be addressed, and instead requires that this assessment be based on the facts and circumstances of an individual fund’s investments. While a fund’s valuation risks should be re-assessed periodically, the Rule does not set a specific required frequency for assessment, which should instead depend on changes in fund investments or in a fund’s strategy or policies, among other things.
Establish and Apply Fair Value Methodologies. The Rule requires that an appropriate fair value methodology be selected and applied in a consistent manner to determine the fair value of investments.[11] In this regard, the key inputs and assumptions specific to each asset class or portfolio holding held by the fund must be specified. In addition, the appropriateness and accuracy of the selected methodologies must be reviewed periodically and adjusted as necessary. Methodologies established by a fund to value investments may be changed if different methodologies are shown to be equally or more representative of the fair value of the investments, and investments within the same asset class may be valued utilizing different appropriate methodologies. In a change from the rule as proposed, a board or valuation designee will not be required to consider the applicability of the selected fair value methodologies to types of fund investments that a fund does not yet hold but intends to hold in the future. In addition, unlike the proposed rule, the Rule does not require the establishment of criteria for determining when market quotations are no longer reliable and therefore not considered readily available.
Test Fair Value Methodologies. Once selected, the appropriateness and accuracy of the fair value methodologies must be tested, with the Rule requiring the identification of testing methods to be used and minimum frequency of testing. However, the Rule does not prescribe the specific testing methods or frequency of testing that should be undertaken, and instead such matters will depend on the facts and circumstances of each fund, as determined by the board or the adviser. The Adopting Release notes that the results of calibration and back-testing can be particularly useful and can help identify issues with methodologies applied by fund service providers.[12] However, the Rule does not specifically require the use of calibration or back-testing.
Evaluate Pricing Services. The Adopting Release notes that, particularly with respect to more complex assets, funds may rely on valuation information provided by third-party pricing services. The Rule requires the oversight and evaluation of such pricing services by the fund’s board or valuation designee, including the establishment of a process for the approval, monitoring and evaluation of each pricing service provider and instituting a process for initiating price “challenges” (i.e., where a fund disagrees with a price provided by a pricing service).[13]
Fair Value Policies and Procedures. In a departure from the rule as proposed, the Rule does not include a separate requirement that a fund adopt written policies and procedures reasonably designed to achieve compliance with the requirements of the Rule. Instead, the Adopting Release explains that Rule 38a-1 under the 1940 Act, which requires a fund’s board to approve the fund’s policies and procedures and those of each adviser and other specified service providers, will by its terms require the adoption and implementation of written policies and procedures reasonably designed to prevent violations of the Rule. The Adopting Release also states that the fair value policies and procedures must be approved by a fund’s board pursuant to Rule 38a-1 and may not be considered material amendments to existing fair value policies and procedures.
Notably, many of the above actions and requirements have previously been implemented by illiquid-focused funds, such as BDCs, which often utilize a committee of independent directors, either through the Audit Committee or a separate Valuation Committee, to oversee the fund’s valuation process. In many cases, this board committee is tasked with approving, among other things, the engagement of third-party pricing services and changes to a fund’s valuation policies and procedures. This group of independent directors also often previews with a fund’s adviser and any third-party pricing services proposed valuations of illiquid investments prior to board determination of fair value.
Other Provisions of the Rule and Related Matters
Recordkeeping
Along with the Rule, the SEC has also adopted Rule 31a-4 under the 1940 Act, relating to recordkeeping requirements in connection with fair value determinations. Rule 31a-4 requires a fund to maintain documentation supporting fair value determinations for at least six years from the time the determination was made (the first two years in an easily accessible place). A fund must maintain such records unless the fund’s board has designated the performance of fair value determinations to the fund’s investment adviser, in which case the investment adviser is required to maintain the records.
Readily Available Market Quotations
As discussed above, for purposes of determining value of an investment, Section 2(a)(41) of the 1940 Act differentiates between whether market quotations are “readily available” or not, but this term is not defined in the 1940 Act or the rules thereunder. The Rule defines a market quotation as being “readily available” for purposes of the 1940 Act only when the quotation is a quoted price (unadjusted) in active markets for identical investments that the fund can access at the measurement date, provided that a quotation will not be readily available if it is not reliable. The Adopting Release notes that a quote would be considered unreliable under the Rule in circumstances where it would require adjustment under U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) or where U.S. GAAP would require consideration of additional inputs in determining the value of the security. If a market quotation is not available, a fair value methodology must be utilized in valuing the investment, and such methodology must also be determined in accordance with U.S. GAAP. The Adopting Release also notes the potential impact of the adoption of the definition of “readily available” on current cross trade practices under Rule 17a-7 under the 1940 Act, given that a security must have a readily available market quotation in order to cross trade under that rule.[14]
Rescission of Prior Commission Releases and Withdrawal of No-Action Letters
As noted in the Adopting Release, the SEC recognizes that, in light of more recent accounting standards and pronouncements, previous SEC guidance, including ASR 113 and ASR 118, as well as certain no-action letters relating to valuation, are no longer necessary and are being rescinded or withdrawn. In addition, certain guidance on thinly traded securities and the use of pricing services issued in 2014 is being rescinded.[15]
Transition Period
The effective date of Rules 2a-5 and 31a-4 is 60 days following their publication in the Federal Register. In order to provide funds and valuation designees with sufficient time to comply with the new rules, the compliance date for the rules is 18 months after the effective date, at which point funds must comply with the new rules and the SEC guidance referenced above will be rescinded. A fund may opt to comply with Rules 2a-5 and 31a-4 any time after the effective date, but in so doing may only rely on the rules and not on any SEC or staff guidance that will be withdrawn or rescinded on the compliance date.
Impact of the Rule on Boards and Advisers
The Rule represents an effort to formalize a more realistic allocation of responsibility for fair value determination as between a fund’s board and its adviser. The Rule has the potential to significantly streamline the fair value process for certain funds that may only hold illiquid investments on an infrequent basis, and may aid open-end funds in better handling their determination of daily net asset value when they hold one or more illiquid investments from time to time. However, as the Rule and the Adopting Release make clear, a board that designates fair value determination to the adviser still retains substantial responsibility to oversee and assess the valuation process. In addition, the Rule requires a delineation between the valuation and portfolio management functions at the adviser level if a board opts to delegate fair value determinations in accordance with the Rule. As a result, BDCs and other funds that invest primarily in illiquid assets may be less likely to take advantage of the delegation of fair value determinations afforded under the Rule, particularly in view of the robust board procedures such funds typically already have in place to handle quarterly valuations.
The Rule also prescribes the information that must be reported by a valuation designee to a board in the case of designation, including relating to any material conflicts of interest an adviser (or other service provider) may encounter in the valuation process and to the adequacy of the resources allocated to the valuation process. In addition, the Rule sets out specific responsibilities of boards and advisers with respect to oversight and evaluation of pricing services. Therefore, while the Rule should help to improve the overall valuation process, it may require boards and advisers to make changes to their current valuation processes to meet the functions and requirements specified in the Rule. In addition, the Rule will eliminate certain flexibility with respect to valuation that funds and boards currently enjoy, given the significant number of requirements in the Rule.
Impact of the Rule on Private Funds
While the Rule applies only to funds regulated under the 1940 Act, there are certain elements of the Rule and the Adopting Release that could be viewed as best practices for all advisers to consider adopting, particularly with respect to potential conflicts of interest in the valuation process. It can be beneficial for the adviser’s fair value determination function to be segregated from the portfolio management of that fund to the extent possible, in order to avoid potential conflicts of interest. Investment advisers may find it challenging to separate their portfolio management personnel from those making fair value determinations, not only from a resources perspective but also in view of the detailed knowledge a fund’s portfolio manager likely has with respect to the illiquid investments a fund holds. The definition of readily available market quotations contained in the Rule can also provide additional clarity to advisers of private funds, and the requirement to evaluate and monitor pricing services in the Rule provides a reminder to all advisers of the importance of doing so.
Next Steps
Funds and their boards and advisers should begin to familiarize themselves with the requirements of the Rule and consider whether designation to perform fair value determinations to a valuation designee is appropriate. In addition, funds that currently engage in cross trades under Rule 17a-7 should assess whether the definition of “readily available market quotations” in the Rule will impact such trading practices.
Authored by Karen Spiegel and Noah B. Aschen.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.
[1] Good Faith Determinations of Fair Value, Investment Company Act Release No. 34128 (Dec. 3, 2020), available here.
[2] In a change from the rule as proposed, a fund’s sub-adviser may not serve as a valuation designee.
[3] Good Faith Determinations of Fair Value, Investment Company Act Release No. 33845 (April 21, 2020), available here.
[4] These investments typically are valued using inputs categorized within Level 3 of the fair value hierarchy established by the Financial Accounting Standards Board in ASC Topic 820.
[5] Section 59 makes Section 2(a)(41) applicable to BDCs.
[6] Unit investment trusts, which do not have a board of directors, can designate the fair value determination to the trust’s trustee or depositor under the Rule.
[7] See Section 2(a)(41)(B)(ii) of the 1940 Act. In ASR 118, the SEC acknowledged that the board may appoint a person to assist with the determination of fair value, but the findings must still be reviewed carefully by the board.
[8] This summary must include any material changes in the assessment and management of valuation risks, including any material changes in conflicts of interest of the valuation designee, any material changes to, or material deviations from, the fair value methodologies, and any material changes to the valuation designee’s process for selecting and overseeing pricing services, as well as any material events related to the valuation designee’s oversight of pricing services.
[9] These reports must include, at a minimum, a summary of the results of the testing of fair value methodologies required under the Rule, and an assessment of the adequacy of resources allocated to the process for determining the fair value of designated investments, including any material changes to the roles or functions of the persons responsible for determining fair value.
[10] Material matters include a significant deficiency or material weakness in the design or effectiveness of the valuation designee’s fair value determination process or material errors in the calculation of net asset value.
[11] The Adopting Release notes that in order to be appropriate under the Rule, a methodology must also be consistent with ASC Topic 820, which covers various valuation approaches and techniques, and should maximize the use of relevant observable inputs and minimize the use of unobservable inputs.
[12] Calibration refers to the process of monitoring for material differences between the price paid for a fair-valued holding as compared to the price calculated for such holding at the time of acquisition by the fund’s fair value methodology. Back-testing compares the fair value of a fund’s investment to observed transaction or other market information, including quotes from dealers or pricing services data.
[13] The Adopting Release notes certain factors that should be considered in such an oversight process, including, among other things: (i) the qualifications, experience and history of the pricing service; (ii) the valuation methods or techniques, inputs, and assumptions used by the pricing service for different asset classes; (iii) the quality of the pricing information provided by the service and the extent to which the service determines its pricing information as close as possible to the time as of which the fund calculates its net asset value; (iv) the process for considering price challenges; (v) potential conflicts of interest of the pricing service and the steps the pricing service takes to mitigate such conflicts; and (vi) the testing processes used by the pricing service.
[14] The Adopting Release states that the definition of readily available market quotations will apply in all contexts under the 1940 Act, including Rule 17a-7, and acknowledges that certain securities may no longer be viewed as having readily available market quotations and will not be available to cross trade under Rule 17a-7. However, the Adopting Release also notes that consideration of potential revisions to Rule 17a-7 is on the SEC’s rulemaking agenda and that public input on this matter is welcome.
[15] Money Market Fund Reform; Amendments to Form PF, Investment Company Act Release No. 31166 (July 23, 2014).
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

The EEOC Releases First Guidance on COVID-19 Vaccination for Employers
ARTICLE / CLIENT ALERT
The EEOC Releases First Guidance on COVID-19 Vaccination for Employers
December 16, 2020
Read time: 29 min
On December 16, 2020, the Equal Employment Opportunity Commission (EEOC) issued its first direct guidance for employers regarding COVID-19 vaccines approved or authorized by the Food and Drug Administration (FDA). The EEOC is responsible for enforcing federal laws against job discrimination and harassment.
This week, as we are seeing the first doses of the COVID-19 vaccination being administered in the United States, the EEOC has answered important questions for employers that are considering their own vaccination programs—including whether the vaccine can be mandatory, what questions employers can ask of employees regarding underlying health conditions with regard to administering the vaccine and what exceptions must be made for employees who object to taking the vaccine for various reasons.
These are the important takeaways for employers under the federal employment laws (note that some states have additional laws that may govern):
- Mandating the vaccine and exceptions to the rule. Employers may require employees to take the COVID-19 vaccine, subject to certain legally protected exceptions for disability and sincerely held religious beliefs.
- The Americans with Disabilities Act (ADA) and Disability Exceptions. With respect to exceptions for disability, the ADA permits employers to have a qualification standard that includes “a requirement that an individual shall not pose a direct threat to the health or safety of individuals in the workplace”—however, if this tends to screen out an individual with a disability, the employer must show that an unvaccinated employee would pose a “direct threat” to the health and safety of the individual or others that cannot be eliminated by a reasonable accommodation (which may include remote work or a temporary leave of absence).
- Title VII and Religious Exceptions. With respect to exceptions for sincerely held religious belief, practice or observance, employers must provide reasonable accommodation for such beliefs unless it would pose an undue hardship (which, for religious belief, is defined as “more than a de minimis cost or burden to the employer”).
- Documentation to Support Request. Employers may generally request that the employee provide supporting documentation to support exception requests for disability or religious reasons.
- Excluding a Worker Where No Reasonable Accommodation Is Possible. If no reasonable accommodation is possible and the employee is unable to be vaccinated, the EEOC states that the employer may “exclude” the worker from the workplace, but this does not necessarily mean that the employer can automatically terminate the worker.
- Administering the vaccine—the ADA. If an employer requires the vaccine, or contracts with a vendor to provide the vaccine, then the pre-vaccination medical screening questions are subject to ADA standards for disability-related inquiries (e., must be job-related and consistent with business necessity); if voluntary, or if the employee receives the vaccine from a third party that does not have a contract with the employer, then these ADA restrictions do not apply.
- Administering the vaccine may violate the Genetic Information Nondiscrimination Act (GINA) if pre-screen questions elicit genetic information. GINA prohibits an employer or a doctor working for the employer from asking employees questions about genetic information. Therefore, to the extent pre-vaccination questions elicit information about genetic information (e.g., questions about immune systems of family members), the EEOC recommends that employers who want to ensure that employees have been vaccinated opt to request proof of vaccination, rather than administer the vaccine themselves.
- Proof of vaccination. Employers may ask employees to show proof of receipt of a COVID-19 vaccination—this is not a disability-related inquiry under the ADA nor is it a request for genetic information under GINA. Employers are encouraged to warn employees not to provide medical or genetic information as part of the proof.
While the EEOC’s guidance answers many questions, it also leaves many important questions unanswered, and raises new ones—including whether healthcare employers will be able to administer the vaccine to their employees if doing so requires a pre-vaccine questionnaire that elicits genetic information; whether employers should mandate the vaccine; and what businesses should be thinking about, and planning for right now, in making these decisions.
Our healthcare, employment and health policy leaders from McDermott Will & Emery and McDermott+Consulting have come together to explore the novel issues that healthcare providers should examine as we move closer to vaccination. View the discussion, “How employers should prepare for the end of the COVID-19 national and public health emergencies.”
The EEOC’s full FAQs on vaccinations follow, and a link to the EEOC’s full guidance on COVID-19, the Americans with Disabilities Act (ADA), and other employment laws can be found in their article, “What You Should Know About COVID-19 and the ADA, the Rehabilitation Act, and Other EEO Laws.”
EEOC Guidance For Employers Regarding the COVID-19 Vaccine (Released 12/16/20)
K. Vaccinations
The availability of COVID-19 vaccinations may raise questions about the applicablilty of various equal employment opportunity (EEO) laws, including the ADA and the Rehabilitation Act, GINA, and Title VII, including the Pregnancy Discrimination Act (see Section J, EEO rights relating to pregnancy). The EEO laws do not interfere with or prevent employers from following CDC or other federal, state, and local public health authorities’ guidelines and suggestions.
ADA and Vaccinations
K.1. For any COVID-19 vaccine that has been approved or authorized by the Food and Drug Administration (FDA), is the administration of a COVID-19 vaccine to an employee by an employer (or by a third party with whom the employer contracts to administer a vaccine) a “medical examination” for purposes of the ADA? (12/16/20)
No. The vaccination itself is not a medical examination. As the Commission explained in guidance on disability-related inquiries and medical examinations, a medical examination is “a procedure or test usually given by a health care professional or in a medical setting that seeks information about an individual’s physical or mental impairments or health.” Examples include “vision tests; blood, urine, and breath analyses; blood pressure screening and cholesterol testing; and diagnostic procedures, such as x-rays, CAT scans, and MRIs.” If a vaccine is administered to an employee by an employer for protection against contracting COVID-19, the employer is not seeking information about an individual’s impairments or current health status and, therefore, it is not a medical examination.
Although the administration of a vaccination is not a medical examination, pre-screening vaccination questions may implicate the ADA’s provision on disability-related inquiries, which are inquiries likely to elicit information about a disability. If the employer administers the vaccine, it must show that such pre-screening questions it asks employees are “job-related and consistent with business necessity.” See Question K.2.
K.2. According to the CDC, health care providers should ask certain questions before administering a vaccine to ensure that there is no medical reason that would prevent the person from receiving the vaccination. If the employer requires an employee to receive the vaccination from the employer (or a third party with whom the employer contracts to administer a vaccine) and asks these screening questions, are these questions subject to the ADA standards for disability-related inquiries? (12/16/20)
Yes. Pre-vaccination medical screening questions are likely to elicit information about a disability. This means that such questions, if asked by the employer or a contractor on the employer’s behalf, are “disability-related” under the ADA. Thus, if the employer requires an employee to receive the vaccination, administered by the employer, the employer must show that these disability-related screening inquiries are “job-related and consistent with business necessity.” To meet this standard, an employer would need to have a reasonable belief, based on objective evidence, that an employee who does not answer the questions and, therefore, does not receive a vaccination, will pose a direct threat to the health or safety of her or himself or others. See Question K.5. below for a discussion of direct threat.
By contrast, there are two circumstances in which disability-related screening questions can be asked without needing to satisfy the “job-related and consistent with business necessity” requirement. First, if an employer has offered a vaccination to employees on a voluntary basis (i.e. employees choose whether to be vaccinated), the ADA requires that the employee’s decision to answer pre-screening, disability-related questions also must be voluntary. 42 U.S.C. 12112(d)(4)(B); 29 C.F.R. 1630.14(d). If an employee chooses not to answer these questions, the employer may decline to administer the vaccine but may not retaliate against, intimidate, or threaten the employee for refusing to answer any questions. Second, if an employee receives an employer-required vaccination from a third party that does not have a contract with the employer, such as a pharmacy or other health care provider, the ADA “job-related and consistent with business necessity” restrictions on disability-related inquiries would not apply to the pre-vaccination medical screening questions.
The ADA requires employers to keep any employee medical information obtained in the course of the vaccination program confidential.
K.3. Is asking or requiring an employee to show proof of receipt of a COVID-19 vaccination a disability-related inquiry? (12/16/20)
No. There are many reasons that may explain why an employee has not been vaccinated, which may or may not be disability-related. Simply requesting proof of receipt of a COVID-19 vaccination is not likely to elicit information about a disability and, therefore, is not a disability-related inquiry. However, subsequent employer questions, such as asking why an individual did not receive a vaccination, may elicit information about a disability and would be subject to the pertinent ADA standard that they be “job-related and consistent with business necessity.” If an employer requires employees to provide proof that they have received a COVID-19 vaccination from a pharmacy or their own health care provider, the employer may want to warn the employee not to provide any medical information as part of the proof in order to avoid implicating the ADA.
ADA and Title VII Issues Regarding Mandatory Vaccinations
K.4. Where can employers learn more about Emergency Use Authorizations (EUA) of COVID-19 vaccines? (12/16/20)
Some COVID-19 vaccines may only be available to the public for the foreseeable future under EUA granted by the FDA, which is different than approval under FDA vaccine licensure. The FDA has an obligation to:
[E]nsure that recipients of the vaccine under an EUA are informed, to the extent practicable under the applicable circumstances, that FDA has authorized the emergency use of the vaccine, of the known and potential benefits and risks, the extent to which such benefits and risks are unknown, that they have the option to accept or refuse the vaccine, and of any available alternatives to the product.
The FDA says that this information is typically conveyed in a patient fact sheet that is provided at the time of the vaccine administration and that it posts the fact sheets on its website. More information about EUA vaccines is available on the FDA’s EUA page.
K.5. If an employer requires vaccinations when they are available, how should it respond to an employee who indicates that he or she is unable to receive a COVID-19 vaccination because of a disability? (12/16/20)
The ADA allows an employer to have a qualification standard that includes “a requirement that an individual shall not pose a direct threat to the health or safety of individuals in the workplace.” However, if a safety-based qualification standard, such as a vaccination requirement, screens out or tends to screen out an individual with a disability, the employer must show that an unvaccinated employee would pose a direct threat due to a “significant risk of substantial harm to the health or safety of the individual or others that cannot be eliminated or reduced by reasonable accommodation.” 29 C.F.R. 1630.2(r). Employers should conduct an individualized assessment of four factors in determining whether a direct threat exists: the duration of the risk; the nature and severity of the potential harm; the likelihood that the potential harm will occur; and the imminence of the potential harm. A conclusion that there is a direct threat would include a determination that an unvaccinated individual will expose others to the virus at the worksite. If an employer determines that an individual who cannot be vaccinated due to disability poses a direct threat at the worksite, the employer cannot exclude the employee from the workplace—or take any other action—unless there is no way to provide a reasonable accommodation (absent undue hardship) that would eliminate or reduce this risk so the unvaccinated employee does not pose a direct threat.
If there is a direct threat that cannot be reduced to an acceptable level, the employer can exclude the employee from physically entering the workplace, but this does not mean the employer may automatically terminate the worker. Employers will need to determine if any other rights apply under the EEO laws or other federal, state, and local authorities. For example, if an employer excludes an employee based on an inability to accommodate a request to be exempt from a vaccination requirement, the employee may be entitled to accommodations such as performing the current position remotely. This is the same step that employers take when physically excluding employees from a worksite due to a current COVID-19 diagnosis or symptoms; some workers may be entitled to telework or, if not, may be eligible to take leave under the Families First Coronavirus Response Act, under the FMLA, or under the employer’s policies. See also Section J, EEO rights relating to pregnancy.
Managers and supervisors responsible for communicating with employees about compliance with the employer’s vaccination requirement should know how to recognize an accommodation request from an employee with a disability and know to whom the request should be referred for consideration. Employers and employees should engage in a flexible, interactive process to identify workplace accommodation options that do not constitute an undue hardship (significant difficulty or expense). This process should include determining whether it is necessary to obtain supporting documentation about the employee’s disability and considering the possible options for accommodation given the nature of the workforce and the employee’s position. The prevalence in the workplace of employees who already have received a COVID-19 vaccination and the amount of contact with others, whose vaccination status could be unknown, may impact the undue hardship consideration. In discussing accommodation requests, employers and employees also may find it helpful to consult the Job Accommodation Network (JAN) website as a resource for different types of accommodations, www.askjan.org. View JAN’s materials specific to COVID-19.
Employers may rely on CDC recommendations when deciding whether an effective accommodation that would not pose an undue hardship is available, but as explained further in Question K.7., there may be situations where an accommodation is not possible. When an employer makes this decision, the facts about particular job duties and workplaces may be relevant. Employers also should consult applicable Occupational Safety and Health Administration standards and guidance. Employers can find OSHA COVID-specific resources at: www.osha.gov/SLTC/covid-19/.
Managers and supervisors are reminded that it is unlawful to disclose that an employee is receiving a reasonable accommodation or retaliate against an employee for requesting an accommodation.
K.6. If an employer requires vaccinations when they are available, how should it respond to an employee who indicates that he or she is unable to receive a COVID-19 vaccination because of a sincerely held religious practice or belief? (12/16/20)
Once an employer is on notice that an employee’s sincerely held religious belief, practice, or observance prevents the employee from receiving the vaccination, the employer must provide a reasonable accommodation for the religious belief, practice, or observance unless it would pose an undue hardship under Title VII of the Civil Rights Act. Courts have defined “undue hardship” under Title VII as having more than a de minimis cost or burden on the employer. EEOC guidance explains that because the definition of religion is broad and protects beliefs, practices, and observances with which the employer may be unfamiliar, the employer should ordinarily assume that an employee’s request for religious accommodation is based on a sincerely held religious belief. If, however, an employee requests a religious accommodation, and an employer has an objective basis for questioning either the religious nature or the sincerity of a particular belief, practice, or observance, the employer would be justified in requesting additional supporting information.
K.7. What happens if an employer cannot exempt or provide a reasonable accommodation to an employee who cannot comply with a mandatory vaccine policy because of a disability or sincerely held religious practice or belief? (12/16/20)
If an employee cannot get vaccinated for COVID-19 because of a disability or sincerely held religious belief, practice, or observance, and there is no reasonable accommodation possible, then it would be lawful for the employer to exclude the employee from the workplace. This does not mean the employer may automatically terminate the worker. Employers will need to determine if any other rights apply under the EEO laws or other federal, state, and local authorities.
Title II of the Genetic Information Nondiscrimination Act (GINA) and Vaccinations
K.8. Is Title II of GINA implicated when an employer administers a COVID-19 vaccine to employees or requires employees to provide proof that they have received a COVID-19 vaccination? (12/16/20)
No. Administering a COVID-19 vaccination to employees or requiring employees to provide proof that they have received a COVID-19 vaccination does not implicate Title II of GINA because it does not involve the use of genetic information to make employment decisions, or the acquisition or disclosure of “genetic information” as defined by the statute. This includes vaccinations that use messenger RNA (mRNA) technology, which will be discussed more below. As noted in Question K.9. however, if administration of the vaccine requires pre-screening questions that ask about genetic information, the inquiries seeking genetic information, such as family members’ medical histories, may violate GINA.
Under Title II of GINA, employers may not (1) use genetic information to make decisions related to the terms, conditions, and privileges of employment, (2) acquire genetic information except in six narrow circumstances, or (3) disclose genetic information except in six narrow circumstances.
Certain COVID-19 vaccines use mRNA technology. This raises questions about genetics and, specifically, about whether such vaccines modify a recipient’s genetic makeup and, therefore, whether requiring an employee to get the vaccine as a condition of employment is an unlawful use of genetic information. The CDC has explained that the mRNA COVID-19 vaccines “do not interact with our DNA in any way” and “mRNA never enters the nucleus of the cell, which is where our DNA (genetic material) is kept.” (See for a detailed discussion about how mRNA vaccines work). Thus, requiring employees to get the vaccine, whether it uses mRNA technology or not, does not violate GINA’s prohibitions on using, acquiring, or disclosing genetic information.
K.9. Does asking an employee the pre-vaccination screening questions before administering a COVID-19 vaccine implicate Title II of GINA? (12/16/20)
Pre-vaccination medical screening questions are likely to elicit information about disability, as discussed in Question K.2., and may elicit information about genetic information, such as questions regarding the immune systems of family members. It is not yet clear what screening checklists for contraindications will be provided with COVID-19 vaccinations.
GINA defines “genetic information” to mean:
- Information about an individual’s genetic tests;
- Information about the genetic tests of a family member;
- Information about the manifestation of disease or disorder in a family member (i.e., family medical history);
- Information about requests for, or receipt of, genetic services or the participation in clinical research that includes genetic services by the an individual or a family member of the individual; and
- Genetic information about a fetus carried by an individual or family member or of an embryo legally held by an individual or family member using assisted reproductive technology.
29 C.F.R. § 1635.3(c). If the pre-vaccination questions do not include any questions about genetic information (including family medical history), then asking them does not implicate GINA. However, if the pre-vaccination questions do include questions about genetic information, then employers who want to ensure that employees have been vaccinated may want to request proof of vaccination instead of administering the vaccine themselves.
GINA does not prohibit an individual employee’s own health care provider from asking questions about genetic information, but it does prohibit an employer or a doctor working for the employer from asking questions about genetic information. If an employer requires employees to provide proof that they have received a COVID-19 vaccination from their own health care provider, the employer may want to warn the employee not to provide genetic information as part of the proof. As long as this warning is provided, any genetic information the employer receives in response to its request for proof of vaccination will be considered inadvertent and therefore not unlawful under GINA. See 29 CFR 1635.8(b)(1)(i) for model language that can be used for this warning.
